M&T Bank Corp Has $3.10 Million Position in Edwards Lifesciences Co. (NYSE:EW)

M&T Bank Corp raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,898 shares of the medical research company’s stock after purchasing an additional 2,678 shares during the quarter. M&T Bank Corp’s holdings in Edwards Lifesciences were worth $3,102,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the 4th quarter valued at $46,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock valued at $2,799,104 over the last three months. 1.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

EW has been the subject of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. The Goldman Sachs Group upped their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Price Performance

NYSE EW opened at $70.36 on Friday. The company has a market cap of $41.37 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $72.26 and its two-hundred day simple moving average is $70.38.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.